RankingsPricing
  1. US-listed companies
  2. ACURA PHARMACEUTICALS, INC
  3. Financials
  4. Cash from financing

ACURA PHARMACEUTICALS, INCACUR

Market cap
P/E ratio
SummaryFinancials
Period EndCash from financing (Million USD)YoY (%)
Dec 31, 20210+45.93%
Dec 31, 20200-80.56%
Dec 31, 20191-21.92%
Dec 31, 20182+43.47%
Dec 31, 20171-148.84%
Dec 31, 2016-3-147.99%
Dec 31, 20155-1117.50%
Dec 31, 2014-1-104.23%
Dec 31, 201312-1283.91%
Dec 31, 2012-1+91.87%
Dec 31, 2011-1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)